CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale CHIEF EXECUTIVE OFFICER sold 243,735 shares at an average $53.82 ($13,116,671)
- 144 Insider Sale of Securities
- 8-K Event Executive or director change
- 4 Planned sale Chief Research Officer sold 209,048 shares at an average $62.83 ($13,135,397)
- 4 Planned sale EVP, CHIEF COMMERCIAL OFFICER sold 283,189 shares at an average $63.06 ($17,857,830)
- 4 Planned sale EVP, Head of R&D & CMO sold 44,674 shares at an average $62.34 ($2,785,021)
- 4 Planned sale Chief Legal Officer and GC sold 37,500 shares at an average $62.34 ($2,337,695)
- 4 Planned sale CHIEF EXECUTIVE OFFICER sold 400,000 shares at an average $63.48 ($25,390,729)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 50,508 shares at an average $62.34 ($3,148,544)
- 4 Planned sale SVP, CHIEF ACCOUNTING OFFICER sold 5,375 shares at an average $62.33 ($335,005)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
Page 1 of 65 · 1,286 filings